EVELO BIOSCIENCES INC's ticker is EVLO and the CUSIP is 299734103. A total of 43 filers reported holding EVELO BIOSCIENCES INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $60,000 | -62.0% | 17,582 | -32.4% | 0.00% | – |
| Q4 2021 | $158,000 | -39.2% | 26,000 | -29.6% | 0.00% | – |
| Q3 2021 | $260,000 | -7.1% | 36,952 | +81.8% | 0.00% | – |
| Q2 2021 | $280,000 | +55.6% | 20,325 | +21.0% | 0.00% | – |
| Q1 2021 | $180,000 | -9.1% | 16,801 | +2.9% | 0.00% | – |
| Q4 2020 | $198,000 | +230.0% | 16,328 | +44.3% | 0.00% | – |
| Q3 2020 | $60,000 | +57.9% | 11,317 | +46.2% | 0.00% | – |
| Q2 2020 | $38,000 | +137.5% | 7,743 | +71.4% | 0.00% | – |
| Q1 2020 | $16,000 | -42.9% | 4,518 | -36.9% | 0.00% | – |
| Q4 2019 | $28,000 | +33.3% | 7,164 | +92.9% | 0.00% | – |
| Q3 2019 | $21,000 | -79.4% | 3,714 | -67.8% | 0.00% | – |
| Q2 2019 | $102,000 | -29.7% | 11,544 | -37.1% | 0.00% | – |
| Q1 2019 | $145,000 | -38.0% | 18,349 | +1.7% | 0.00% | – |
| Q4 2018 | $234,000 | -15.8% | 18,048 | -21.2% | 0.00% | – |
| Q3 2018 | $278,000 | +25.8% | 22,895 | +21.7% | 0.00% | – |
| Q2 2018 | $221,000 | – | 18,807 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 484,953 | $1,823,000 | 4.61% |
| Flagship Pioneering Inc. | 18,233,403 | $68,558,000 | 3.21% |
| HARBOURVEST PARTNERS LLC | 1,763,505 | $6,622,000 | 3.20% |
| Alphabet Inc. | 1,060,495 | $3,982,000 | 0.26% |
| Larson Financial Group LLC | 20,042 | $75,000 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 133,500 | $501,000 | 0.01% |
| CREDIT SUISSE AG/ | 1,500,117 | $5,633,000 | 0.01% |
| FMR LLC | 3,220,853 | $12,094,000 | 0.00% |
| VICTORY CAPITAL MANAGEMENT INC | 177,856 | $668,000 | 0.00% |
| Legal & General Group Plc | 1,522 | $6,000 | 0.00% |